Skip to content
DataLookout
Menu

NCT07895524

A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 1 with changes below, 1 re-verified with no change.

  1. Study First Submitted

Endpoints

Primary

Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12
Timeframe: Week 12

Secondary (9)

Number of Participants Who Experience One or More Adverse Events (AEs)
Number of Participants Who Discontinue Study Intervention Due to an AE
Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12
Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP) at Week 12
Show 4 moreShow less
Change from Baseline in DAS28-CRP
Percentage of Participants Achieving LDA based on DAS28-CRP
Percentage of Participants Achieving Clinical Remission Based on DAS28-CRP
Change From Baseline in the HAQ-DI Score

Arms and interventions

Period 1: MK-8690Experimental

Participant will receive MK-8690 subcutaneous (SC) for 12 weeks

Period 1: PlaceboPlacebo comparator

Participant will receive placebo SC for 12 weeks

Extension PeriodExperimental

After completing Period 1 participants will receive MK-8690 SC for 40 weeks.

Combination products: MK-8690, Placebo

Drugs: Methotrexate (MTX)